Kala Expects Dry Eye Data by 2017 Year-end

Kala Pharmaceuticals is expecting by the end of 2017 topline clinical data from its ongoing Phase III trial of KPI-121 0.25% for treatment of dry eye, chairman and CEO Mark Iwicki said at the OIS@AAO 2017 Public Device and Biopharma Company Showcase. KPI-121 0.25% has the potential to be the first approved first-line therapy for treatment of dry eye and may be complimentary to chronic maintenance therapies, he continued. Kala is also developing Inveltys (KPI-121 1%) for treatment of pain and inflammation after anterior segment surgery. The new drug application was submitted to the Food and Drug Administration in October 2017, Iwicki said.